MRF and magnetic field application results in antigen-specific T cell accumulation.

<p>(<b>A</b>) Experimental model for antigen-specific responses following MRF and magnet treatments: BALB/c mice received Renca-HA on the right flank s.c. When tumors reached the desired size, mice first received 2×10⁶ CD8(+)-HA-Tet⁺ cells i.v. One day following Tg-CD8(+) T cell transfer, mice were administered MRF or PBS intratumor. 24 h later, some groups are left untreated or receive magnetic treatments for 5 min a day for 5 consecutive days. After 5 days of daily magnetic field treatments, tumors or tumor-DLNs were collected and assayed by flow cytometry. (<b>A</b>) Percentage and (<b>B</b>) total number of transgenic HA-Tg-CD8(+)-CD25+ T cells in Renca-HA tumor. (<b>C</b>) DLNs from the same mice in (<b>A–B</b>) were analyzed for homing of HA-Tg-CD8(+)CD25+ T cells. Data representative of one single experiment (n = 3 mice/group in PBS or MRF group and n = 5 mice in the MRF/magnet group). One-way ANOVA. ** P<0.01, *** P<0.001, n.s: not significant.